A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Active:	No
Cancer Type:	Kidney Cancer Unknown Primary	NCT ID:	NCT05805501
Trial Phases:	Phase II	Protocol IDs:	BO43936 (primary) NCI-2023-03569
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT05805501

Summary

This study will evaluate the safety of tobemstomig (RO7247669) in combination with
axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab
and axitinib in participants with previously untreated, unresectable locally advanced or
metastatic clear-cell renal cell carcinoma (ccRCC).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.